Phase 2 B-ALL Clinical Trials
12 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–12 of 12 trials
Recruiting
Phase 2
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaB-ALL
National Cancer Institute (NCI)20 enrolled1 locationNCT07328503
Recruiting
Phase 1Phase 2
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca83 enrolled26 locationsNCT07109219
Recruiting
Phase 1Phase 2
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)130 enrolled1 locationNCT05442515
Recruiting
Phase 1Phase 2
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca236 enrolled80 locationsNCT06137118
Recruiting
Phase 1Phase 2
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
B-cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD115 enrolled1 locationNCT05480449
Recruiting
Phase 2Phase 3
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Stephan Grupp MD PhD133 enrolled1 locationNCT04276870
Recruiting
Phase 2
Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
B-ALL
Hebei Senlang Biotechnology Inc., Ltd.59 enrolled1 locationNCT07244406
Recruiting
Phase 2Phase 3
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Childhood Leukemia, Acute LymphoblasticB-cell Acute Lymphoblastic Leukemia (B-ALL)Acute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China3,000 enrolled27 locationsNCT06882057
Recruiting
Phase 1Phase 2
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
AML (Acute Myelogenous Leukemia)B-ALLMyeloma, Multiple+3 more
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting
Phase 1Phase 2
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
B-ALL
Chongqing Precision Biotech Co., Ltd40 enrolled1 locationNCT04781634
Recruiting
Phase 2Phase 3
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Childhood Leukemia, Acute LymphoblasticB-cell Acute Lymphoblastic Leukemia (B-ALL)Acute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China1,800 enrolled26 locationsNCT06764238